Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation
PLOS Medicine · 2026
DOI: 10.1371/journal.pmed.1004882 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Medicine, 2026. Verfasst von Lise Jamieson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannes…. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background South Africa accounts for 20% of global HIV infections. Six-monthly injectable lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) has superior efficacy to oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and similar efficacy to 2-monthly injectable cabotegravir (CAB). With LEN’s regulatory approval, South Africa faces critical implementation decisions amid constrained domestic resources and reduced international funding. We evaluated the epidemiological impact, cost-effectiveness, and optimal populations for LEN roll-out in South Africa. Methods and findings Using Thembisa v4.8, a deterministic compartmental HIV transmission model, we simulated the impact of LEN scale-up, expanded oral TDF/FTC, and CAB scale-up, compared to a baseline of current TDF/FTC provision over 20 years (2026–2045) in South Africa. We modelled PrEP among women, including adolescent girls and young women (AGYW), female sex workers (FSW), pregnant and breastfeeding women (PBFW), men who have sex with men (MSM), and heterosexual men. For TDF/FTC scale-up, we doubled baseline initiation rates. For LEN and CAB, conservative and optimistic scenarios assumed initiation rates similar to or double those under TDF/FTC scale-up, respectively. Duration of use varied by subpopulation under TDF/FTC (3–6 months), conservative (LEN: 6–12 months, CAB: 4–8 months), and optimistic (LEN: 12–24 months, CAB: 8–16 months) scenarios. We modelled strategies to maximise impact of ~500,000 LEN doses allocated for 2026–2027, and national roll-out by subpopulations. We compared LEN cost-effectiveness to other HIV interventions, including antiretroviral treatment (ART). Costs are presented from the South African government’s perspective in undiscounted 2025 United States Dollars (USD). Providing LEN to 1.7–2.9 million South Africans annually averted 19%–31% of infections and saved 3%–5% of life years lost to HIV, reaching incidence
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- South African Centre for Epidemiological Modelling and Analysis (SACEMA), Centre for Epidemic Response and Innovation (CERI), School for Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, So…
- Centre for Integrated Data and Epidemiological Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
- Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
- National Department of Health, Pretoria, South Africa.
ORCID-Profile: Lise Jamieson, Leigh F Johnson, Jeffrey W Imai-Eaton, Hasina Subedar, Linda-Gail Bekker, Gesine Meyer-Rath
Förderung
- Bill and Melinda Gates Foundation
Zitieren
APA
Jamieson, L., Johnson, L. F., Imai-Eaton, J. W., Subedar, H., Bekker, L. G., & Meyer-Rath, G. (2026). Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004882
Vancouver
Jamieson L, Johnson LF, Imai-Eaton JW, Subedar H, Bekker LG, Meyer-Rath G. Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation. PLOS Medicine. 2026. doi:10.1371/journal.pmed.1004882
BibTeX
@article{Jamieson2026,
author = {Jamieson, Lise and Johnson, Leigh F and Imai-Eaton, Jeffrey W and Subedar, Hasina and Bekker, Linda-Gail and Meyer-Rath, Gesine},
title = {Optimising scale-up of injectable lenacapavir for HIV pre-exposure prophylaxis in South Africa: A modelling study and economic evaluation},
journal = {PLOS Medicine},
year = {2026},
doi = {10.1371/journal.pmed.1004882}
}
EUVIMED